HOUSTON INNOVATORS PODCAST EPISODE 194

Houston innovator dedicated to fostering community within local founders

Every month, Adrianne Stone of Bayou City Startups hosts a happy hour for startup founders to create a safe space to network, collaborate, commensurate, and more. Photo courtesy of Adrianne Stone

Starting a company can be daunting and lonely, but entrepreneurs — at least those who call Houston home — have a monthly opportunity to connect with fellow founders thanks to Adrianne Stone.

Stone, who's had a varied career from getting her PhD in Translational Biology & Molecular Medicine at Baylor College of Medicine and joining the 23andMe team as a scientist to supporting founders at Capital Factory, launched Bayou City Startups last year to help connect Houston founders over beers. Now, Stone shares on the Houston Innovators Podcast that her monthly Bayou City Startups meetups attract over 50 attendees on average.

"Being the venture associate with Capital Factory in Houston, I'd seen what the Houston ecosystem had to offer. There were events — happy hours, coffee meet-ups, all these things," Stone says. "But it was not just a casual networking event usually. I wanted a consistent community where I could show up and say, 'guys, I had the worst week,' to people who got where I was coming from and who could commensurate or lean in and help."

Stone observes a need for that type of community more in Houston than Silicon Valley, where she worked when she was at 23andMe. The Bayou City has less of a concentrated startup scene.

"Houston and the Bay Area could not be more different in a lot of ways," she explains. "Everybody I met had a startup in California — it didn't matter if they worked somewhere else, they had a startup.

"I would love to see more of that here in Houston," Stone continues. "Our founders in Houston are super scrappy. They do so much with so little, and we just do not have the amount of capital floating around this ecosystem that you do in SF. I'd love to see more of that here too."

The next opportunity to network with Bayou City Startups is Tuesday, July 18, from 5 to 7 pm at Kirby Ice House. Stone says she picks different types of bars all over the city to meet people where they are and to offer a variety of locations. She adds that she's always up for co-hosts and partners.

Part of what makes Stone, who consults with startups in a professional capacity, an interesting point of view is her "zig-zagging" career. She's held a wide range of roles at an even wider range of professions before she made it to tech startups.

“The through line for me is following my curiosity,” she says on the show. “I was interested in politics, so I did a White House internship. I had a background in science, so I wanted to do something with it, so I went into teaching. Through teaching, I got interested in web development and blogging, so that's how I made the transition into the digital space.”

Her advice to fellow zig-zaggers? Knowing when to say no to things.

"You can overcommit yourself and you're going to burnout or drop the ball or end up disappointing people," she says, admitting she's had to get better at this herself. "Practice saying no. Make it your default. Founders tend to say yes first."

Stone shares more about her career and her observations on Houston's startup ecosystem on the show. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted